STAR Ph3 Study of NVL-655 Compared to Alectinib in First Line Tx with ALK+ NSCLC (ALKAZAR)

A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR) (NVL-655-04)